Status:
COMPLETED
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Multiple Myeloma
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
Eligibility Criteria
Inclusion
- Age 21 or above with diagnosis of multiple myeloma (myeloma is almost unheard of in patients less than 21 years of age).
- Scheduled to receive conditioning chemotherapy with melphalan followed by upfront or salvage autologous peripheral blood hematopoietic stem cell transplantation
- English or Spanish speaking
- Calculated creatinine clearance \> 40 mL/min
Exclusion
- Prior head and neck radiation.
- Severe periodontal infection. Poor oral hygiene and dentition as determined by pre HCT dental assessment.
- Pregnancy
- Patients with pre-existing moderate-severe dysgeusia
Key Trial Info
Start Date :
August 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 12 2023
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT03276481
Start Date
August 28 2017
End Date
July 12 2023
Last Update
July 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021